Could 2 years of hormone therapy be enough for some breast cancers?
NCT ID NCT07153757
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a shorter course of hormone therapy (2-3 years) works as well as the standard longer treatment for women with a very low-risk, early-stage breast cancer. About 2,900 women will be randomly assigned to either the shorter or standard treatment. The goal is to see if the shorter option can maintain cancer control while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
endocrine therapy (hormone-blocking drugs like tamoxifen or aromatase inhibitors)
What this could lead to
If successful, this could show that many women with low-risk breast cancer can safely stop hormone therapy after 2-3 years, reducing side effects and improving quality of life.
What could go wrong
This is a large phase 3 trial, but it only includes very low-risk patients, so results may not apply to others. There is a small chance that shorter therapy could lead to higher recurrence rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, 200032, China